摘要
目的分析信迪利单抗治疗晚期非小细胞肺癌的临床疗效。方法选取60例晚期非小细胞肺癌患者作为研究对象,按照随机摸球法展开分组,即分为对照组(30例)、观察组(30例)。对照组采取紫杉醇与顺铂联合化疗方案(TP方案)治疗,观察组采取信迪利单抗联合TP方案治疗。对比两组患者近期疗效、毒副反应发生情况及治疗前后T淋巴细胞亚群检测情况、碱性成纤维细胞生长因子(bFGF)与血管内皮生长因子(VEGF)水平、生存质量评分。结果观察组的客观缓解率、疾病控制率分别为36.67%、83.33%,均高于对照组的10.00%、40.00%(P<0.05)。治疗后,观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)较治疗前升高,CD8^(+)较治疗前下降,且观察组CD3^(+)(55.05±6.07)%、CD4^(+)(37.21±5.80)%、CD4^(+)/CD8^(+)(2.03±0.39)均高于对照组的(35.39±5.56)%、(20.16±5.30)%、(0.98±0.47),CD8^(+)(17.60±3.79)%低于对照组的(21.72±4.44)%(P<0.05);对照组治疗后CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)较治疗前下降(P<0.05),CD8^(+)与治疗前对比无统计学意义(P>0.05)。治疗后,两组bFGF、VEGF水平均较治疗前明显下降,且观察组bFGF(13.03±4.58)ng/L、VEGF(256.38±76.01)ng/L均低于对照组的(19.26±5.06)、(309.71±95.71)ng/L(P<0.05)。观察组腹泻、肺炎、肝功能异常、骨髓抑制、蛋白尿、输液反应等发生率与对照组对比无统计学意义(P>0.05)。治疗后,两组精力、一般健康状况、躯体疼痛、生理职能以及社会功能评分均较治疗前明显升高,且观察组精力评分(62.53±7.06)分、一般健康状况评分(66.84±6.47)分、躯体疼痛评分(67.91±7.09)分、生理职能评分(58.50±6.09)分、社会功能评分(73.50±6.47)分均高于对照组的(55.96±6.89)、(62.91±6.26)、(62.12±6.23)、(51.40±6.40)、(69.93±4.32)分(P<0.05)。结论信迪利单抗用于治疗晚期非小细胞肺癌具有显著疗效,可改善患者T淋巴细胞亚群指标以及bFGF、VEGF水平,毒副反应发生风�
Objective To analyze the clinical efficacy of sintilimab in the treatment of advanced nonsmall-cell lung cancer.Methods 60 patients with advanced non-small-cell lung cancer were selected as research subjects and divided into a control group(30 cases)and an observation group(30 cases)according to random ball-touching method.The control group was treated with paclitaxel and cisplatin combined chemotherapy(TP regimen),and the observation group was treated with sintilimab combined with TP regimen.Patients in both groups were compared in terms of short-term efficacy,occurrence of side effects,detection of T lymphocyte subsets,levels of basic fibroblast growth factor(bFGF)and vascular endothelial growth factor(VEGF),and the quality of life score before and after treatment.Results The objective remission rate and disease control rate of the observation group were 36.67%and 83.33%,which were higher than 10.00%and 40.00%of the control group(P<0.05).After treatment,CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the observation group were higher than those before treatment,while CD8^(+)was lower than that before treatment;the observation group had CD3^(+)of(55.05±6.07)%,CD4^(+)of(37.21±5.80)%and CD4^(+)/CD8^(+)of(2.03±0.39),which were higher than(35.39±5.56)%,(20.16±5.30)%and(0.98±0.47)in the control group;CD8^(+)was(17.60±3.79)%in the observation group,which was lower than(21.72±4.44)%in the control group(P<0.05).In the control group,CD3^(+),CD4^(+),CD4^(+)/CD8^(+)decreased after treatment compared with those before treatment(P<0.05),and CD8^(+)was not statistically significant compared with that before treatment(P>0.05).After treatment,the levels of bFGF and VEGF in both groups decreased significantly compared with those before treatment;the observation group had bFGF of(13.03±4.58)ng/L and VEGF of(256.38±76.01)ng/L,which were lower than(19.26±5.06)and(309.71±95.71)ng/L in the control group(P<0.05).The incidence of diarrhea,pneumonia,liver function abnormality,bone marrow suppression,proteinuria,and infusion reaction in
作者
苗军程
MIAO Jun-cheng(Jinxiang County People's Hospital,Jining 272200,China)
出处
《中国实用医药》
2024年第14期20-24,共5页
China Practical Medicine
关键词
恶性肿瘤
非小细胞肺癌
信迪利单抗
临床疗效
Malignant tumors
Non-small-cell lung cancer
Sintilimab
Clinical efficacy
